Progenics Pharmaceuticals (Progenics Pharmaceuticals) Cash-to-Debt : 0.56 (As of Mar. 2020)

View and export this data going back to 1997. Start your Free Trial

What is Progenics Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Progenics Pharmaceuticals's cash to debt ratio for the quarter that ended in Mar. 2020 was 0.56.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Progenics Pharmaceuticals couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2020.

The historical rank and industry rank for Progenics Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

PGNX's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.5
* Ranked among companies with meaningful Cash-to-Debt only.

Progenics Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Progenics Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Progenics Pharmaceuticals Cash-to-Debt Chart

Progenics Pharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

2.81

1.82

3.09

0.77

Progenics Pharmaceuticals Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Cash-to-Debt	Get a 7-Day Free Trial															1.86	1.46	1.14	0.77	0.56

Competitive Comparison of Progenics Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, Progenics Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Progenics Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Progenics Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Progenics Pharmaceuticals's Cash-to-Debt falls into.

Progenics Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Progenics Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2019 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	42.049	/	(7.716	+	46.915)
	=	0.77

Progenics Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Mar. 2020 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	29.531	/	(7.856	+	44.998)
	=	0.56

Progenics Pharmaceuticals (NAS:PGNX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Progenics Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Progenics Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Progenics Pharmaceuticals (Progenics Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progenics Pharmaceuticals Inc (NAS:PGNX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

One World Trade Center, Suite J, 47th Floor, New York, NY, USA, 10007

Website

http://www.progenics.com

Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.

Executives

Asha Das	officer: Chief Medical Officer	C/O PROGENICS PHARMACEUTICALS, INC., 1 WORLD TRADE CENTER, 47TH FL, SUITE J, NEW YORK NY 10007
Ann L. Macdougall	director	C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Karen Jean Ferrante	director	150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818
Heinz Christoph Maeusli	director	SCHUETZENWEG 3, ENGELBURG V8 9032
Gerard Ber	director	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Eric J Ende	director	C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Bradley L Campbell	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Balaji Venkataraman	10 percent owner, other: See Explanation of Responses	FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Virinder Nohria	10 percent owner, other: See Explanation of Responses	1055 POWERS PLACE, SUITE B, ALPHARETTA GA 30009
Nicole Williams	director
David A Scheinberg	director	325 CENTRAL PARK W, APT 38, NEW YORK NY 10025
Michael D Kishbauch	director	18 CHERRYVILLE RD, FLEMINGTON NJ 08822
Broadfin Healthcare Master Fund Ltd	10 percent owner	C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Kevin Kotler	10 percent owner	C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc	10 percent owner	300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022